ad image

Company Info

Janssen Pharmaceutical Companies

Janssen Pharmaceutical Companies

Drug Discovery & Development

Overview

At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science.
Janssen Pharmaceutical Companies
Contributions
25 Contributions1 / 2
Janssen Pharmaceutical Companies
COVID-19 Vaccine

Johnson & Johnson Announces Agreement with U.S. Government for 100 Million Doses of Investigational COVID-19 Vaccine

Janssen Pharmaceutical Companies

PR-M08-20-NI-11-1359Aug 06, 2020
Janssen Pharmaceutical Companies
FDA Approval

Janssen Announces U.S. FDA Approval of STELARA® (ustekinumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

Janssen Pharmaceutical Companies

PR-M10-19-NI-032-2050Oct 22, 2019
Janssen Pharmaceutical Companies
Drug Development

Janssen Submits Application to U.S. FDA Seeking Approval of ERLEADA® (apalutamide) for Patients with Metastatic Castration-Sensitive Prostate Cance

Janssen Pharmaceutical Companies

PR-M05-19-NI-001May 01, 2019
Janssen Pharmaceutical Companies
New Drug Application

Janssen Submits Supplemental New Drug Application to U.S. FDA for INVOKANA® (canagliflozin) for the Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes

Janssen Pharmaceutical Companies

PR-M04-19-NI-008Apr 02, 2019
Janssen Pharmaceutical Companies
Real-World Analysis

XARELTO® Significantly Reduced Ischemic Stroke in Real-World Meta-Analysis of Non-Vitamin K Antagonist Oral Anticoagulants

Janssen Pharmaceutical Companies

PR-M03-19-NI-044Mar 15, 2019
Janssen Pharmaceutical Companies
FDA

FDA Advisory Committee Recommends Approval of SPRAVATO™ (esketamine) Nasal Spray CIII for Adults with Treatment-Resistant Depression

Janssen Pharmaceutical Companies

PR-M02-19-NI-030Feb 14, 2019
Janssen Pharmaceutical Companies
FDA Approval

U.S. FDA Approves DARZALEX® (daratumumab) Split-Dosing Regimen

Janssen Pharmaceutical Companies

PR-M02-19-NI-028Feb 13, 2019
Janssen Pharmaceutical Companies
Phase 3

New DARZALEX® (daratumumab) Phase 3 Study Shows Efficacy and Safety Data of Anti-CD38 Monoclonal Antibody in Patients with Newly Diagnosed Multiple Myeloma

Janssen Pharmaceutical Companies

PR-M12-18-NI-019Dec 06, 2018
Janssen Pharmaceutical Companies
Oncology

New Phase 3 CASSINI Data Presented on the Use of XARELTO® (rivaroxaban) for Venous Thromboembolism (VTE) Prevention in High-Risk Cancer Patients

Janssen Pharmaceutical Companies

PR-M12-18-NI-020Dec 06, 2018
Janssen Pharmaceutical Companies
Depression

New Data Presented at Psych Congress 2018 Sheds Light on the Significant Economic Burden of Treatment-Resistant Depression Amongst U.S. Veterans

Janssen Pharmaceutical Companies

PR-M10-18-NI-104Oct 30, 2018
Janssen Pharmaceutical Companies
Clinical Data

Janssen Announces New Three-Year TREMFYA® (Guselkumab) Data Demonstrates Stably Maintained Rates of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis

Janssen Pharmaceutical Companies

PR-M10-18-NI-073Oct 22, 2018
Janssen Pharmaceutical Companies
New Drug Application

Janssen Submits New Drug Application to U.S. FDA Seeking Approval of Erdafitinib for the Treatment of Metastatic Urothelial Cancer

Janssen Pharmaceutical Companies

PR-M09-18-NI-083Sep 26, 2018
Janssen Pharmaceutical Companies
Study Results

Janssen Reports Positive Topline Results for ATLAS Phase III Study of a Novel, Long Acting Injectable Two-Drug Regimen for the Treatment of HIV-1

Janssen Pharmaceutical Companies

PR-M09-18-NI-045Sep 17, 2018
Janssen Pharmaceutical Companies
Regulatory

Janssen Submits U.S. & EU Regulatory Applications Seeking Approval of DARZALEX® (daratumumab) Split Dosing Regimen

Janssen Pharmaceutical Companies

PR-M08-18-NI-093Aug 23, 2018
Janssen Pharmaceutical Companies
Positive Opinion

Janssen Receives Positive CHMP Opinion for Darzalex®▼ (daratumumab) as Frontline Treatment for Newly Diagnosed Patients with Multiple Myeloma

Janssen Pharmaceutical Companies

PR-M08-18-NI-007Aug 02, 2018
Janssen Pharmaceutical Companies
FDA Approval

Janssen Announces U.S. FDA Approval of SYMTUZA™ (D/C/F/TAF), the First and Only Complete Darunavir-Based Single-Tablet Regimen for the Treatment of HIV-1 Infection

Janssen Pharmaceutical Companies

PR-M07-18-NI-061Jul 19, 2018
Janssen Pharmaceutical Companies

Janssen Announces Initiation of Phase 1b/2 Clinical Development Program Evaluating JNJ-68284528 CAR-T Cells for the Treatment of Multiple Myeloma

Janssen Pharmaceutical Companies

PR-M06-18-NI-005Jun 01, 2018
Janssen Pharmaceutical Companies
Real-World Study

New Real-World Study Finds Long-Term XARELTO® (rivaroxaban) Use Resulted in Fewer Strokes and Systemic Emboli

Janssen Pharmaceutical Companies

PR-M05-18-NI-101May 28, 2018
Janssen Pharmaceutical Companies
Commission Approval

Janssen Announces European Commission Approval of JULUCA®▼ (dolutegravir/rilpivirine), the First Two-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV-1

Janssen Pharmaceutical Companies

PR-M05-18-NI-088May 23, 2018
Janssen Pharmaceutical Companies
Clinical Trial

ERLEADA™ Significantly Reduced Risk of Prostate Specific Antigen (PSA) Progression in Patients with Non-Metastatic Castration-Resistant Prostate Cancer

Janssen Pharmaceutical Companies

PR-M05-18-NI-086May 23, 2018
1 / 2
0 Contributors1 / 0

No authors found

1 / 0